Jump to content

Giant cell arteritis

From Wikipedia, the free encyclopedia
(Redirected from Horton disease, juvenile)

Giant cell arteritis
Other namesTemporal arteritis, cranial arteritis,[1] Horton disease,[2] senile arteritis,[1] granulomatous arteritis[1]
The arteries of the face and scalp
SpecialtyRheumatology, emergency medicine, Immunology
SymptomsHeadache, pain over the temples, flu-like symptoms, double vision, difficulty opening the mouth[3]
ComplicationsBlindness, aortic dissection, aortic aneurysm, polymyalgia rheumatica[4]
Usual onsetAge greater than 50[4]
CausesInflammation of the small blood vessels within the walls of larger arteries[4]
Diagnostic methodBased on symptoms and blood tests, confirmed by biopsy of the temporal artery[4]
Differential diagnosisTakayasu arteritis,[5] stroke, primary amyloidosis[6]
TreatmentSteroids, bisphosphonates, proton-pump inhibitor[4]
PrognosisLife expectancy (typically normal)[4]
Frequency~ 1 in 15,000 people a year (> 50 years old)[2]

Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory autoimmune disease of large blood vessels.[4][7] Symptoms may include headache, pain over the temples, flu-like symptoms, double vision, and difficulty opening the mouth.[3] Complications can include blockage of the artery to the eye with resulting blindness, as well as aortic dissection, and aortic aneurysm.[4] GCA is frequently associated with polymyalgia rheumatica.[4]

The cause is unknown.[2] The underlying mechanism involves inflammation of the small blood vessels that supply the walls of larger arteries.[4] This mainly affects arteries around the head and neck, though some in the chest may also be affected.[4][8] Diagnosis is suspected based on symptoms, blood tests, and medical imaging, and confirmed by biopsy of the temporal artery.[4] However, in about 10% of people the temporal artery is normal.[4]

Treatment is typical with high doses of steroids such as prednisone or prednisolone.[4] Once symptoms have resolved, the dose is decreased by about 15% per month.[4] Once a low dose is reached, the taper is slowed further over the subsequent year.[4] Other medications that may be recommended include bisphosphonates to prevent bone loss and a proton-pump inhibitor to prevent stomach problems.[4]

It affects about 1 in 15,000 people over the age of 50 per year.[2] The condition mostly occurs in those over the age of 50, being most common among those in their 70s.[4] Females are more often affected than males.[4] Those of northern European descent are more commonly affected.[5] Life expectancy is typically normal.[4] The first description of the condition occurred in 1890.[1]

Signs and symptoms

[edit]

Common symptoms of giant cell arteritis include:

The inflammation may affect blood supply to the eye; blurred vision or sudden blindness may occur. In 76% of cases involving the eye, the ophthalmic artery is involved, causing arteritic anterior ischemic optic neuropathy.[14]

Giant cell arteritis may present with atypical or overlapping features.[15] Early and accurate diagnosis is important to prevent ischemic vision loss. Therefore, this condition is considered a medical emergency.[15]

While studies vary as to the exact relapse rate of giant cell arteritis, relapse of this condition can occur.[16] It most often happens at low doses of prednisone (<20 mg/day), during the first year of treatment, and the most common signs of relapse are headache and polymyalgia rheumatica.[16]

Associated conditions

[edit]

The varicella-zoster virus (VZV) antigen was found in 74% of temporal artery biopsies that were GCA-positive, suggesting that the VZV infection may trigger the inflammatory cascade.[17]

The disorder may co-exist (in about half of cases) with polymyalgia rheumatica (PMR),[13] which is characterized by sudden onset of pain and stiffness in muscles (pelvis, shoulder) of the body and is seen in the elderly. GCA and PMR are so closely linked that they are often considered to be different manifestations of the same disease process. PMR usually lacks the cranial symptoms, including headache, pain in the jaw while chewing, and vision symptoms, that are present in GCA.[18]

Giant cell arteritis can affect the aorta and lead to aortic aneurysm and aortic dissection.[19] Up to 67% of people with GCA having evidence of an inflamed aorta, which can increase the risk of aortic aneurysm and dissection.[19] There are arguments for the routine screening of each person with GCA for this possible life-threatening complication by imaging the aorta. Screening should be done on a case-by-case basis based on the signs and symptoms of people with GCA.[19]

Mechanism

[edit]

The pathological mechanism is the result of an inflammatory cascade that is triggered by an as of yet undetermined cause resulting in dendritic cells in the vessel wall recruiting T cells and macrophages to form granulomatous infiltrates.[19] These infiltrates erode the middle and inner layers of the arterial tunica media leading to conditions such as aneurysm and dissection.[19] Activation of T helper 17 (Th17) cells involved with interleukin (IL) 6, IL-17, IL-21 and IL-23 play a critical part; specifically, Th17 activation leads to further activation of Th17 through IL-6 in a continuous, cyclic fashion.[19] This pathway is suppressed with glucocorticoids,[20] and more recently it has been found that IL-6 inhibitors also play a suppressive role.[19]

Diagnosis

[edit]

Physical exam

[edit]
Intermediate magnification micrograph showing giant cell arteritis in a temporal artery biopsy. The arterial lumen is seen on the left. A giant cell is seen on the right at the interface between the thickened intima and media.  H&E stain

Laboratory tests

[edit]

Biopsy

[edit]
Histopathology of giant cell vasculitis in a cerebral artery. Elastica-stain.

The gold standard for diagnosing temporal arteritis is biopsy, which involves removing a small part of the vessel under local anesthesia and examining it microscopically for giant cells infiltrating the tissue.[23] However, a negative result does not definitively rule out the diagnosis; since the blood vessels are involved in a patchy pattern, there may be unaffected areas on the vessel and the biopsy might have been taken from these parts. Unilateral biopsy of a 1.5–3 cm length is 85-90% sensitive (1 cm is the minimum).[24] Characterised as intimal hyperplasia and medial granulomatous inflammation with elastic lamina fragmentation with a CD4+ predominant T cell infiltrate, currently biopsy is only considered confirmatory for the clinical diagnosis, or one of the diagnostic criteria.[11]

Medical imaging

[edit]

Radiological examination of the temporal artery with ultrasound yields a halo sign. Contrast-enhanced brain MRI and CT are generally negative in this disorder. Recent studies have shown that 3T MRI using super high resolution imaging and contrast injection can non-invasively diagnose this disorder with high specificity and sensitivity.[25] Temporal artery thickening on imaging has been demonstrated to have highest positive likelihood ratios for GCA when compared with other non invasive diagnostic tests.[26]

Early recognition

[edit]

Women and men approximately 45 years old and who suffer from several complaints (at least 5 of the 16 symptoms)[27] listed below could have giant cell arteritis.

  • Fatigue and apathy
  • Stiffness in joints and/or muscles
  • Painful jaws when chewing
  • Sensitive scalp
  • Physical malaise and/or weakness
  • Bloated arteries of the temples
  • Headaches, migraine
  • Tongue problems
  • Bleakness, depression
  • Changed eyesight
  • Poor or lack of appetite
  • Reduced eyesight, blindness
  • Unusual loss of weight
  • A temperature
  • Unusual perspiration
  • Night sweats

Treatment

[edit]

GCA is considered a medical emergency due to the potential of irreversible vision loss.[15] Corticosteroids, typically high-dose prednisone (1 mg/kg/day), should be started as soon as the diagnosis is suspected (even before the diagnosis is confirmed by biopsy) to prevent irreversible blindness secondary to ophthalmic artery occlusion. Steroids do not prevent the diagnosis from later being confirmed by biopsy, although certain changes in the histology may be observed towards the end of the first week of treatment and are more difficult to identify after a couple of months.[28] The dose of corticosteroids is generally slowly tapered over 12–18 months.[22] Oral steroids are at least as effective as intravenous steroids,[29] except in the treatment of acute visual loss where intravenous steroids appear to offer significant benefit over oral steroids.[30] Short-term side effects of prednisone are uncommon but can include mood changes, avascular necrosis, and an increased risk of infection.[31] Some of the side effects associated with long-term use include weight gain, diabetes mellitus, osteoporosis, avascular necrosis, glaucoma, cataracts, cardiovascular disease, and an increased risk of infection.[32][33] It is unclear whether adding a small amount of aspirin is beneficial or not as it has not been studied.[34] Injections of tocilizumab may also be used.[35] Tocilizumab is a humanized antibody that targets the interleukin-6 receptor, which is a key cytokine involved in the progression of GCA.[36] Tocilizumab has been found to be effective at minimizing both recurrence, and flares of GCA when used both on its own and with corticosteroids.[36] Long term use of tocilizumab requires further investigation.[36][37] Tocilizumab may increase the risk of gastrointestinal perforation and infections, however it does not appear that there are more risks than using corticosteroids.[36][37]

Epidemiology

[edit]

Giant cell arteritis typically only occurs in those over the age of 50;[4] particularly those in their 70s.[22] It affects about 1 in 15,000 people over the age of 50 per year.[2] It is more common in women than in men, by a ratio of 2:1,[4] and more common in those of Northern European descent, as well as in those residing further from the Equator.[5]

Disease impact

[edit]

Giant cell arteritis and its treatment impact on people's lives because of symptoms, adverse effects of GCs and disruption to normal life.[38] People with GCA have previously ranked ‘losing sight in both eyes permanently’, ‘having intense or severe pain’ and ‘feeling weak, tired or exhausted’ as important quality of life domains.[39] Generic measures of disease impact such as SF36 may not always capture the disease specific aspects of GCA impact such as visual loss or systemic complications.[40] The Outcome Measures in Rheumatology (OMERACT) Large Vessel Vasculitis Working Group have identified the need for a disease-specific patient-reported outcome measure (PROM) for GCA.[41] Recently, a new disease specific measure of health-related quality of life in GCA has been developed.[42][43] The GCA-PRO has been shown to have robust validity and reliability in a cross-sectional study and can discriminate between different sub-groups of patients. This is likely going to help to capture the impact of disease and treatment in clinical trials and clinical practice.[43]

Terminology

[edit]

The terms "giant cell arteritis" and "temporal arteritis" are sometimes used interchangeably, because of the frequent involvement of the temporal artery. However, other large vessels such as the aorta can be involved.[44] Giant-cell arteritis is also known as "cranial arteritis" and "Horton's disease".[45] The name (giant cell arteritis) reflects the type of inflammatory cell involved.[46]

References

[edit]
  1. ^ a b c d Nussinovitch U (2017). The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches. Academic Press. p. 367. ISBN 978-0-12-803268-8. Archived from the original on 2017-10-22.
  2. ^ a b c d e "Orphanet: Giant cell arteritis". www.orpha.net. Archived from the original on 14 September 2017. Retrieved 14 September 2017.
  3. ^ a b "Giant Cell Arteritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 13 April 2017. Archived from the original on 22 October 2017. Retrieved 21 October 2017.
  4. ^ a b c d e f g h i j k l m n o p q r s t u v Weyand CM, Goronzy JJ (July 2014). "Clinical practice. Giant-cell arteritis and polymyalgia rheumatica". The New England Journal of Medicine. 371 (1): 50–57. doi:10.1056/NEJMcp1214825. PMC 4277693. PMID 24988557.
  5. ^ a b c Johnson RJ, Feehally J, Floege J (2014). Comprehensive Clinical Nephrology E-Book. Elsevier Health Sciences. p. 300. ISBN 9780323242875. Archived from the original on 2017-10-22.
  6. ^ Ferri FF (2010). Ferri's Differential Diagnosis E-Book: A Practical Guide to the Differential Diagnosis of Symptoms, Signs, and Clinical Disorders. Elsevier Health Sciences. p. 195. ISBN 978-0-323-08163-4. Archived from the original on 2017-10-22.
  7. ^ Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. (January 2013). "2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides". Arthritis and Rheumatism. 65 (1): 1–11. doi:10.1002/art.37715. PMID 23045170. S2CID 20891451.
  8. ^ "Giant Cell Arteritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 13 April 2017. Archived from the original on 22 October 2017. Retrieved 21 October 2017.
  9. ^ Moutray TN, Williams MA, Best JL (August 2008). "Suspected giant cell arteritis: a study of referrals for temporal artery biopsy". Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie. 43 (4): 445–448. doi:10.3129/i08-070. PMID 18711459.
  10. ^ Sainuddin S, Saeed NR (December 2008). "Acute bilateral tongue necrosis--a case report". The British Journal of Oral & Maxillofacial Surgery. 46 (8): 671–672. doi:10.1016/j.bjoms.2008.03.027. PMID 18499311.
  11. ^ a b Zadik Y, Findler M, Maly A, Rushinek H, Czerninski R (January 2011). "A 78-year-old woman with bilateral tongue necrosis". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 111 (1): 15–19. doi:10.1016/j.tripleo.2010.09.001. PMID 21176820.
  12. ^ Walz-Leblanc BA, Ameli FM, Keystone EC (March 1991). "Giant cell arteritis presenting as limb claudication. Report and review of the literature". The Journal of Rheumatology. 18 (3): 470–472. PMID 1856819.
  13. ^ a b Hunder GG. "Polymyalgia rheumatica and giant cell (temporal) arteritis". uptodate.com. Wolters Kluwer. Archived from the original on 25 September 2015. Retrieved 23 September 2015.
  14. ^ Hayreh (April 3, 2003). "Ocular Manifestations of GCA". University of Iowa Health Care. Archived from the original on 2007-10-25. Retrieved 2007-10-15.
  15. ^ a b c Rana AQ, Saeed U, Khan OA, Qureshi AR, Paul D (October 2014). "Giant cell arteritis or tension-type headache?: A differential diagnostic dilemma". Journal of Neurosciences in Rural Practice. 5 (4): 409–411. doi:10.4103/0976-3147.140005. PMC 4173245. PMID 25288850.
  16. ^ a b "UpToDate". www.uptodate.com. Retrieved 2019-11-25.
  17. ^ Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, et al. (May 2015). "Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis". Neurology. 84 (19): 1948–1955. doi:10.1212/WNL.0000000000001409. PMC 4433460. PMID 25695965.
  18. ^ "Giant cell arteritis". BMJ Best Practice. Retrieved 2019-11-25.
  19. ^ a b c d e f g Chen JJ, Warrington KJ, Garrity JA, Prasad S (September 2017). "Is Routine Imaging of the Aorta Warranted in Patients With Giant Cell Arteritis?". Journal of Neuro-Ophthalmology. 37 (3): 314–319. doi:10.1097/WNO.0000000000000538. PMID 28614098. S2CID 3747982.
  20. ^ Weyand CM, Goronzy JJ (July 2014). Solomon CG (ed.). "Clinical practice. Giant-cell arteritis and polymyalgia rheumatica". The New England Journal of Medicine. 371 (1): 50–57. doi:10.1056/NEJMcp1214825. PMC 4277693. PMID 24988557.
  21. ^ a b c d e "Giant Cell Arteritis". The Lecturio Medical Concept Library. 26 November 2020. Retrieved 23 July 2021.
  22. ^ a b c d Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. (March 2020). "British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis". Rheumatology. 59 (3): e1–e23. doi:10.1093/rheumatology/kez672. hdl:10044/1/76450. PMID 31970405.
  23. ^ Cahais J, Houdart R, Lupinacci RM, Valverde A (June 2017). "Operative technique: Superficial temporal artery biopsy". Journal of Visceral Surgery. 154 (3): 203–207. doi:10.1016/j.jviscsurg.2017.05.001. PMID 28601496.
  24. ^ Ypsilantis E, Courtney ED, Chopra N, Karthikesalingam A, Eltayab M, Katsoulas N, et al. (November 2011). "Importance of specimen length during temporal artery biopsy". The British Journal of Surgery. 98 (11): 1556–1560. doi:10.1002/bjs.7595. PMID 21706476. S2CID 20149393.
  25. ^ Bley TA, Uhl M, Carew J, Markl M, Schmidt D, Peter HH, et al. (October 2007). "Diagnostic value of high-resolution MR imaging in giant cell arteritis". AJNR. American Journal of Neuroradiology. 28 (9): 1722–1727. doi:10.3174/ajnr.A0638. PMC 8134183. PMID 17885247.
  26. ^ van der Geest KS, Sandovici M, Brouwer E, Mackie SL (October 2020). "Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis". JAMA Internal Medicine. 180 (10): 1295–1304. doi:10.1001/jamainternmed.2020.3050. PMC 7432275. PMID 32804186.
  27. ^ "Symptomatix Home". www.symptomatrix-eng.eu. Retrieved 2023-05-07.
  28. ^ Font RL, Prabhakaran VC (February 2007). "Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases". The British Journal of Ophthalmology. 91 (2): 204–209. doi:10.1136/bjo.2006.101725. PMC 1857614. PMID 16987903.
  29. ^ "BestBets: Steroids and Temporal Arteritis". Archived from the original on 2009-02-27.
  30. ^ Chan CC, Paine M, O'Day J (September 2001). "Steroid management in giant cell arteritis". The British Journal of Ophthalmology. 85 (9): 1061–1064. doi:10.1136/bjo.85.9.1061. PMC 1724128. PMID 11520757.
  31. ^ Richards RN (March 2008). "Side effects of short-term oral corticosteroids". Journal of Cutaneous Medicine and Surgery. 12 (2): 77–81. doi:10.2310/7750.2008.07029. PMID 18346404. S2CID 30995207.
  32. ^ Youssef J, Novosad SA, Winthrop KL (February 2016). "Infection Risk and Safety of Corticosteroid Use". Rheumatic Disease Clinics of North America. 42 (1): 157–176. doi:10.1016/j.rdc.2015.08.004. PMC 4751577. PMID 26611557.
  33. ^ Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS (2016-04-02). "Long-term side effects of glucocorticoids". Expert Opinion on Drug Safety. 15 (4): 457–465. doi:10.1517/14740338.2016.1140743. PMID 26789102. S2CID 39396172.
  34. ^ Mollan SP, Sharrack N, Burdon MA, Denniston AK (August 2014). "Aspirin as adjunctive treatment for giant cell arteritis". The Cochrane Database of Systematic Reviews. 2014 (8): CD010453. doi:10.1002/14651858.CD010453.pub2. PMC 10589060. PMID 25087045.
  35. ^ "Press Announcements - FDA approves first drug to specifically treat giant cell arteritis". www.fda.gov. Retrieved 10 February 2018.
  36. ^ a b c d Mariano VJ, Frishman WH (2018). "Tocilizumab in Giant Cell Arteritis". Cardiology in Review. 26 (6): 321–330. doi:10.1097/CRD.0000000000000204. PMID 29570475. S2CID 4227514.
  37. ^ a b Rinden T, Miller E, Nasr R (July 2019). "Giant cell arteritis: An updated review of an old disease". Cleveland Clinic Journal of Medicine. 86 (7): 465–472. doi:10.3949/ccjm.86a.18103. PMID 31291180.
  38. ^ Liddle J, Bartlam R, Mallen CD, Mackie SL, Prior JA, Helliwell T, et al. (August 2017). "What is the impact of giant cell arteritis on patients' lives? A UK qualitative study". BMJ Open. 7 (8): e017073. doi:10.1136/bmjopen-2017-017073. PMC 5724062. PMID 28838902.
  39. ^ Hellmann DB, Uhlfelder ML, Stone JH, Jenckes MW, Cid MC, Guillevin L, et al. (December 2003). "Domains of health-related quality of life important to patients with giant cell arteritis". Arthritis and Rheumatism. 49 (6): 819–825. doi:10.1002/art.11464. PMID 14673969.
  40. ^ Jobard S, Magnant J, Blasco H, Ferreira-Maldent N, Griffoul I, Diot E, et al. (September 2017). "Quality of life of patients treated for giant cell arteritis: a case-control study". Clinical Rheumatology. 36 (9): 2055–2062. doi:10.1007/s10067-017-3619-4. PMID 28405843. S2CID 21925882.
  41. ^ Aydin SZ, Direskeneli H, Sreih A, Alibaz-Oner F, Gul A, Kamali S, et al. (December 2015). "Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12". The Journal of Rheumatology. 42 (12): 2465–2469. doi:10.3899/jrheum.141144. PMC 4668221. PMID 26077399.
  42. ^ Robson JC, Almeida C, Dawson J, Bromhead A, Dures E, Guly C, et al. (October 2021). "Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure". Rheumatology. 60 (10): 4671–4680. doi:10.1093/rheumatology/keab076. PMC 8487303. PMID 33528002.
  43. ^ a b Ndosi M, Almeida C, Dawson J, Dures E, Greenwood R, Bromhead A, et al. (January 2024). "Validation of a patient-reported outcome measure for giant cell arteritis". Rheumatology. 63 (1): 181–189. doi:10.1093/rheumatology/kead201. PMC 10765151. PMID 37144946.
  44. ^ Walter MA, Melzer RA, Graf M, Tyndall A, Müller-Brand J, Nitzsche EU (May 2005). "[18F]FDG-PET of giant-cell aortitis". Rheumatology. 44 (5): 690–691. doi:10.1093/rheumatology/keh551. PMID 15728420.
  45. ^ James WD, Elston DM, Berger TG, Andrews GC (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. p. 840. ISBN 978-0-7216-2921-6. OCLC 663444979.
  46. ^ "giant cell arteritis" at Dorland's Medical Dictionary
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Giant_cell_arteritis&oldid=1253280659"